Daniel Neureiter, MD

Institute of Pathology

University Clinics Salzburg

Paracelus Medical Private University

Epigenetic and developmental pathways in cancer

Within CCS we focus on investigations of signal cascades in a variety of tumor entities applying different molecular techniques (such as western blot, immunhistochemistry, tissue micro arrays as well as cell-cycle-analysis) in-vitro and in-vivo as well as in-situ to characterize specific cellular and molecular pathways of differentiation, proliferation and apoptosis.

The experimental and translational investigation of epigenetic regulatory mechanism like DNA-methylation, Histone-acetylation and miRNA profiling (i) in solid tumors of the gastro-intestinal-tract, especially of the hepato-biliary-pancreatic system, (ii) as well as in hematologic malignancies (MDS, MALT-lymphoma, diffuse large B-cell lymphoma) are the recent scientific focuses of the research group of Neureiter, Illig and Klieser at the Institute of Pathology (SALK/PMU). 

In the last year, it was shown that epigenetic deregulations are key events in human cancerogenesis; additionally, linkages between epigenetic alterations and tumor pathways (such as β-Catenin-WNT or Hedgehog pathway) were established. Moreover, national and international co-operations exist to solve these complex scientific questions resulting in many publications in peer-review journals. The final aim of these investigations is to select that promising tumor sub-entity with the best therapeutic effect by targeted therapy in future.

Epigenetic and embryonic pathways in solid and lymphatic tumors